PVmed (Perception Vision)’s Post

Get ready for an enriching experience at the #NYVALVES2024 Summit! Dive into a knowledge-packed week with sessions you can't miss. Discover advanced techniques and evidence-based practices through live-case demonstrations, hands-on training, debates, and the latest updates in the field. At Conformal Medical, our CLAAS® device aims to reduce the risk of stroke without the need for anticoagulants in patients with atrial fibrillation.  Meet with our team to learn about our next-gen device and our confirmed seal rate of 97.7% seal without significant (>3mm) leaks at 12 months, comparing favorably with marketed devices¹ from our Early Feasibility Study. See you there!  #CardiovascularInnovation #LAAtherapy #ConformalMedical #MedicalAdvancements #Cardiology #LAAO #data #conformalmedical #claas #Afib #NYVALVES2024 #electrophysiology #interventionalcardiology   1. Gray W, Conformal Early Feasibility Study: 12 Months Results. TCT 2023   CAUTION: Investigational Device The CLAAS System is limited by Federal (or United States) law to investigational use.

Each year, 1M+ individuals throughout Europe experience a stroke, one of the leading causes of disability. As the population continues to age and risk factors increase, effective stroke management across the whole #StrokeCare pathway – from diagnosis and emergency treatment to rehabilitation and prevention of recurrent strokes – has never been more critical. As part of our pursuit to lead where medicine is going, @Johnson & Johnson is partnering with industry and leading European health institutions in a new project funded by the Innovative Health Initiative (IHI), a partnership between the EU and Europe’s life science industries, known as the #UMBRELLAProject. Alongside UMBRELLA_IHI partners, we’ll work to bring forth AI-driven innovations to improve diagnosis, accelerate treatment, and reduce long-term complications, ultimately improving the quality of life of stroke patients and #StrokeSurvivorsEurope. I’m so proud of our cross-functional team contributing to this project—including our Johnson & Johnson Innovative Medicine #DataScience & #DigitalHealth R&D team, as well as Clinical Development, Medical Affairs, and Johnson & Johnson MedTech—and course, our external collaborators on UMBRELLA. We are ready to close gaps in care and deliver tailored solutions from diagnosis to rehabilitation over the next five years and beyond in stroke care. Interested to learn more about our work with UMBRELLA and how it is changing the future of stroke care: https://lnkd.in/ehNv-ZWx

We are humbled to be featured by A*STAR - Agency for Science, Technology and Research's Biomedical Sciences Industry Partnership Office (#BMSIPO) as a success story on their website. At #Mirxes, we have achieved several key milestones over the past 10 years, including the launch and commercialisation of our flagship GASTROClear, the world's first approved molecular blood test used to detect early-stage stomach cancer. This breakthrough is a testament to our dedication to making advanced diagnostic solutions accessible globally. However, this is just the beginning. Our mission is to advance healthcare through early detection of cancers and diseases, and we have a long way to go. We will continue to push boundaries and develop even more innovative and wide-ranging early detection solutions. We are grateful to our partners, stakeholders and the entire A*STAR community for their unwavering support. Their belief in our mission has been instrumental in our growth. When approached by BMSIPO recently, we were excited and more than willing to share our experiences with other companies, especially fellow Singapore companies, embarking on the biomedical journey. Whether you are starting out or just seeking some industry insights, we are here to share what we know and provide encouragement 💪 While the journey may be challenging, the rewards — saving lives and improving health outcomes — make every obstacle worthwhile. Read more about Mirxes and our journey here: https://lnkd.in/gdgAS3jj #preventivehealthcare #precisionmedicine #biotech #researchanddevelopment #earlydetectionsaveslives #healthcare #cancerearlydetection #miRNA #research #multiomics #biomedical

something concrete and promising to transform stroke care in future.. take a read.

Technological advancement with AI-based solutions 🤖 can help to better evaluate the amount of « big » data 📈, to find patterns for better diagnosis, and to facilitate follow up and monitoring. Looking forward to the first UMBRELLA_IHI results!

Just announced that exciting results will be presented at #ESMO 2024 Presidential Symposium from #PIONeeR Project (Precision Immuno-Oncology for advanced Non-Small Cell Lung Cancer Patients with PD-(L)1 ICI Resistance) -Presentation Number: LBA8, Presidential Symposium III: Eyes to the future. PIONeeR is a major international hospital-university research project addressing the critical challenge of resistance to PD-1(L1) immune checkpoint inhibitors (#ICIs) in over 450 patients with advanced non-small cell lung cancer (#NSCLC), including a biomarker program (> 400 biomarkers). Trial (NCT03493581, https://lnkd.in/d4yA7mV7) is evaluating responses in patients who had either first or latter lines PD(L)1 inhibitor mono therapy or chemo combo combination and developed resistance. https://lnkd.in/dyfZYTxJ #ESMO 2024 #NSCLC #Nivolumab #Pembrolizumab #Atezolizumab #Durvalumab

We are excited to share our latest research at the upcoming Health Technology Assessment international (HTAi) 2024 event in Seville! Be sure to mark your calendars and book a #braindate with the presenters. 1. A European Value Assessment Framework For Next Generation Sequencing And Comprehensive Genomic Profiling Oncology Diagnostics - Oral Presentation 🗓 Date & Time: Tuesday, 18 June 2024, 14:35 – 15:35 📍 Location: Room – Andalucia 5, Barceló Convention Centre Description: In a joint collaboration between the MTRG and IECS - Instituto de Efectividad Clínica y Sanitaria, led by Dr Panos Kanavos and Dr Prof. Federico Augustovski, MD, MSc, PhD, we developed a value assessment framework to provide transparent and explicit criteria for the evaluation and coverage of NGS/CGP diagnostics in European oncology settings. Presenter: Madeleine Haig 2. Incentives To Incorporate Innovation Into Care Delivery Processes: A Scoping Review And SWOT Analysis - Poster Presentation 📍 Location: Poster Exhibition Area, Atrio 3 Description: Part of HI-PRIX HORIZON, this research investigates the strengths, weaknesses, opportunities, and threats of financial and non-financial incentive mechanisms that aim to improve access to innovative medical technologies. Presenter: Madeleine Haig 3. Do Patient Contributions Matter? A Thematic Document Analysis of NICE Ultra-Rare Disease Appraisals - Poster Presentation 📍 Location: Poster Exhibition Area, Atrio 3 Description: This study analyses inputs from patient organisations and patient experts in technology appraisals for ultra-rare diseases in the UK and seeks to understand how they are taken into account in NICE final recommendations. Presenter: Arianna Gentilini See you there! #HTAi2024 #healthtechnologyassessment #pharmaceuticalpolicy #NICE #patientorganisations #valueassessment

Great news! 🎉 The Ubbo Emmius Foundation (UEF) has funded HTRIC €18.4 million euros. This funding supports innovative research in health technology and strengthens the Northern Netherlands as a leading region in this field. Being a partner of HTRIC we are very happy with this development. Our dean Wiro Niessen says: “This investment enables us to accelerate realizing our ambition: a healthier future for all. HTRIC combines science, technology and practice to bring medical innovations to patients quickly and effectively.” With a focus on research themes such as molecular diagnostics, imaging, targeted therapy, and materials, HTRIC aims to create impactful solutions like light-activated cancer therapy and minimally invasive implants. These advancements bring us closer to safer, more effective, and personalized patient care. #HealthTech #Innovation #Collaboration #HTRIC #UMCG #UbboEmmiusFoundation 

Day 3 at #PEGSEurope2024 in Barcelona also marks the close of a scientifically inspiring conference. I once heard that when asked how any conference was, the answer should be: “The talks were great, I learnt a lot!” At #PEGSEurope2024 this was the simple reality. Here are 6 learnings: 1)     T cell engagers (TCE) are here to stay and we Evotec are on the right path, at the right time, with our CD2 bispecific platforms. If you missed our posters, reach out to my colleagues James Hallinan or Priyanka Sahasrabudhe. 2)     Leaders in the field at J&J and AZ are spearheading new frontiers. J&J are taking the learnings from the already impressive clinical responses to bispecific CD3 TCEs in B cell hematological cancers and forging the next steps with their trispecific CD3 TCE +/- bispecific co-stimulatory engagers with the hope to extend overall response rates. AZ’s #GPS platform is turning armed tumor-infiltrating effector/memory T cells that were hitherto considered as by-stander T cells into a pool of anti-tumor effectors. This is an impressive approach to watch out for. 3)     B cells can contribute to orchestrating the anti-tumor response: Mestag are going after tertiary lymphoid structures by targeting LTBR via a bispecific. 4)     CAR-Ts engineered to produce their own IL-10 uncover almost enigmatic biology to mediate some of the most impressive pre-clinical and early clinical anti-tumor responses I have ever seen. 5)     AI/ML approaches are powerful tools for predicting and improving the biophysical properties of antibodies. Still, the experts are currently undecided whether AI/ML platforms can generate, de novo, functional target-specific antibodies. Time may tell. 6)     The now very hot ADC lane has clearly intersected with the bispecific antibody lane and new ground will be broken going forward. …And so much more…! Thanks to all the organizers of #PEGSEurope2024 for putting together such a well-organized, stimulating program and facilitating an interactive atmosphere.

🗣 The Institute of Communications and Computer Systems (ICCS), a partner of the ONCODIR project, was recently invited to present at a conference titled "Implementation of Digital Tools for Oncological Quality of Care – Barriers and Facilitators." This conference was organized by Kapa3 as Final Meeting of the E-Health4Cancer project. Dr. Dimitra Dionysiou, Head of the Health Technologies Department at iSENSE Group, ICCS, presented the collaborative co-design process with patients in ONCODIR and ONCOSCREEN (two Horizon Europe projects that ICCS is involved in) to an engaged audience. ▶ For more details and the full presentation on "Patients as Co-creators of Innovative Technologies in R&I Projects of Horizon Europe: The Case of ONCOSCREEN and ONCODIR," please visit: https://lnkd.in/dr3Y99wD #DigitalTools #Oncology #AI #DigitalHealth #CRC #ColorectalCancer #CancerResearch #HorizonEurope